Literature DB >> 33241594

Simulation model of disease incidence driven by diagnostic activity.

Marcus Westerberg1,2, Rolf Larsson1, Lars Holmberg2,3, Pär Stattin2, Hans Garmo2.   

Abstract

It is imperative to understand the effects of early detection and treatment of chronic diseases, such as prostate cancer, regarding incidence, overtreatment and mortality. Previous simulation models have emulated clinical trials, and relied on extensive assumptions on the natural history of the disease. In addition, model parameters were typically calibrated to a variety of data sources. We propose a model designed to emulate real-life scenarios of chronic disease using a proxy for the diagnostic activity without explicitly modeling the natural history of the disease and properties of clinical tests. Our model was applied to Swedish nation-wide population-based prostate cancer data, and demonstrated good performance in terms of reconstructing observed incidence and mortality. The model was used to predict the number of prostate cancer diagnoses with a high or limited diagnostic activity between 2017 and 2060. In the long term, high diagnostic activity resulted in a substantial increase in the number of men diagnosed with lower risk disease, fewer men with metastatic disease, and decreased prostate cancer mortality. The model can be used for prediction of outcome, to guide decision-making, and to evaluate diagnostic activity in real-life settings with respect to overdiagnosis and prostate cancer mortality.
© 2020 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  incidence; population-based; prostate cancer; real-life; screening; simulation model

Year:  2020        PMID: 33241594      PMCID: PMC7894333          DOI: 10.1002/sim.8833

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  45 in total

Review 1.  Calibration methods used in cancer simulation models and suggested reporting guidelines.

Authors:  Natasha K Stout; Amy B Knudsen; Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

2.  Screening for prostate cancer remains controversial.

Authors:  Jennifer R Stark; Lorelei Mucci; Kenneth J Rothman; Hans-Olov Adami
Journal:  BMJ       Date:  2009-09-24

3.  Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.

Authors:  Rebecka Arnsrud Godtman; Erik Holmberg; Hans Lilja; Johan Stranne; Jonas Hugosson
Journal:  Eur Urol       Date:  2014-12-31       Impact factor: 20.096

4.  High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm.

Authors:  Rebecka Godtman; Erik Holmberg; Johan Stranne; Jonas Hugosson
Journal:  Scand J Urol Nephrol       Date:  2011-04-05

5.  The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.

Authors:  Karl Stattin; Fredrik Sandin; Ola Bratt; Mats Lambe
Journal:  J Urol       Date:  2015-07-17       Impact factor: 7.450

6.  Second round results of the Finnish population-based prostate cancer screening trial.

Authors:  Tuukka Mäkinen; Teuvo L J Tammela; Ulf-Håkan Stenman; Liisa Määttänen; Jussi Aro; Harri Juusela; Paula Martikainen; Matti Hakama; Anssi Auvinen
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

7.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Authors:  Gerrit Draisma; Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Elisabeth Wever; Roman Gulati; Eric Feuer; Harry de Koning
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

8.  Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.

Authors:  Walter Cazzaniga; Hans Garmo; David Robinson; Lars Holmberg; Anna Bill-Axelson; Pär Stattin
Journal:  BJU Int       Date:  2018-10-25       Impact factor: 5.588

9.  Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.

Authors:  Jan Adolfsson; Hans Garmo; Eberhard Varenhorst; Göran Ahlgren; Christer Ahlstrand; Ove Andrén; Anna Bill-Axelson; Ola Bratt; Jan-Erik Damber; Karin Hellström; Magnus Hellström; Erik Holmberg; Lars Holmberg; Jonas Hugosson; Jan-Erik Johansson; Bill Petterson; Magnus Törnblom; Anders Widmark; Pär Stattin
Journal:  Scand J Urol Nephrol       Date:  2007

10.  How to measure temporal changes in care pathways for chronic diseases using health care registry data.

Authors:  Eugenio Ventimiglia; Mieke Van Hemelrijck; Lars Lindhagen; Pär Stattin; Hans Garmo
Journal:  BMC Med Inform Decis Mak       Date:  2019-05-30       Impact factor: 2.796

View more
  3 in total

1.  Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort.

Authors:  Oskar Bergengren; Marcus Westerberg; Lars Holmberg; Pär Stattin; Anna Bill-Axelson; Hans Garmo
Journal:  JAMA Netw Open       Date:  2021-05-03

2.  Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths.

Authors:  Magdalena Lycken; Oskar Bergengren; Linda Drevin; Hans Garmo; Marcus Westerberg; Elin Axén; Johan Stranne; Lars Holmberg; Anna Bill-Axelson
Journal:  Eur Urol Open Sci       Date:  2022-05-28

3.  Simulation model of disease incidence driven by diagnostic activity.

Authors:  Marcus Westerberg; Rolf Larsson; Lars Holmberg; Pär Stattin; Hans Garmo
Journal:  Stat Med       Date:  2020-11-25       Impact factor: 2.373

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.